Navigation Links
Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Date:9/11/2012

MADISON, Wis., Sept. 11, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the second cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.  The second two-patient cohort was successfully dosed with approximately 40 mCi of HOT, triggering enrollment into the third cohort at approximately 60 mCi.  Details of the trial design are available on www.clinicaltrials.gov ID: NCT01495663, or at www.novelos.com in the 'Clinical Trials' section.  Glenn Liu, M.D., Associate Professor of Medicine and Director of the Cancer Therapy Discovery and Development (Phase I) Program at the University of Wisconsin Carbone Cancer Center, is the trial's principal investigator.  Detailed trial results are expected to be presented at a scientific venue at a later date.

"Data from this second cohort indicates that HOT was well-tolerated, without any dose-limiting or sub-dose-limiting toxicities, enabling enrollment of the third cohort as planned," said Dr. Liu.  "We continue to observe selective uptake of HOT in cancerous tumors where it persists for at least 21 days."

"We are pleased with HOT's safety profile and selective cancerous tumor uptake and retention in this second cohort at a dose of approximately 40 mCi," said Kim Hawkins, Vice President of Clinical Development of Novelos.  "We now look forward to evaluating HOT at approximately 60 mCi in cancer patients with advanced solid tumors, as per the trial protocol."

"We expect to begin HOT Phase 2 proof-of-concept trials in the third quarter of 2013 in cancer patients that have significant unmet medical need," said Harry
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... -- Columbia Laboratories, Inc. (Nasdaq: CBRX ) (" ... pharmaceutical company focused on pharmaceuticals for women,s health, today ... ROTH Conference, which will take place from March 8-11 ... Point, California . Management,s presentation will take place ... (12:00 p.m. Eastern Time) in the Promenade room. ...
(Date:3/3/2015)... 3, 2015 /CNW/ - Sante Medical Hair Restoration is ... hair transplantation. The ARTAS Robotic System ... effectively extracts hair for transplantation. This latest development ... results, with no linear scar. "The ... of hair restoration surgery." says Dr. Louis ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... of the "Telemedicine and Mobile Healthcare Solutions, ... - 2020" report to their offering. ... are all terms that pertain to the use ... provide remote clinical/non-clinical healthcare services. They form the ...
Breaking Medicine Technology:No linear scar. Permanent results. 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3
... ANTONIO, April 17, 2012  Mission Pharmacal announced today ... technology licensing agreement with EffRx Pharmaceuticals SA, Freienbach, ... (alendronate sodium) Effervescent Tablets in the ... Drug Administration recently approved BINOSTO to treat osteoporosis ...
... SPRING, Md., April 16, 2012     Sunpeaks Ventures, Inc. ... Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, ... be an official exhibitor at the Thrombosis and Hemostasis ... May 3-5, 2012 at the Hyatt Regency Chicago.  ...
Cached Medicine Technology:Mission Pharmacal and EffRx Bring New Osteoporosis Medication to the United States and Canada 2Mission Pharmacal and EffRx Bring New Osteoporosis Medication to the United States and Canada 3Mission Pharmacal and EffRx Bring New Osteoporosis Medication to the United States and Canada 4Sunpeaks Ventures to Exhibit Clotamin at the first-ever Thrombosis and Hemostasis Summit of North America 2
(Date:3/3/2015)... Dan E. Chambers, an experienced Los Angeles criminal ... recently spoke on the radio to give his insights into ... Independent Journal Review radio show “The Right Mics” chose Chambers ... and now as a criminal defense attorney would provide him ... and sentencing of this high-profile case. , During the ...
(Date:3/3/2015)... The report “Alopecia – Pipeline Review, ... for Alopecia. Alopecia is the loss of hair. Alopecia ... of alopecia. Causes for alopecia include aging, genetics, illness, ... include male pattern hair loss, female diffuse hair loss, ... classified as focal or diffuse and by the presence ...
(Date:3/3/2015)... The first week of March is Sleep ... event brings recognition to a rarely discussed problem that ... to the Centers for Disease Control , 70 million ... another. Too little or unrestful sleep is associated with ... depression, and even a higher likelihood of obesity. ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 The ... better predict antidepressant treatment outcomes for patients with ... than any of the individual genes that comprise ... investigators from the Mayo Clinic and Assurex Health, ... , The proprietary technology of the GeneSight ...
(Date:3/3/2015)... 03, 2015 The North ... to grow from $1,224.6 million to $1,694.6 ... 2014 and 2019. , Browse through the ... market for an analysis of industry trends ... tables and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , ...
Breaking Medicine News(10 mins):Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 2Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 2Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 4Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 6Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3
... who will respond best to interferon beta treatments , ... explain why some multiple sclerosis (MS) patients respond to ... Starting with 206 southern European patients with relapsing-remitting MS, ... compared the DNA of patients whose symptoms were reduced ...
... largest comparison of blood samples collected from healthy individuals ... common Toxoplasma gondii parasite, carried by cats and farm ... report on the study, conducted among U.S. military personnel ... and Johns Hopkins Childrens Center appears in the January ...
... wetlands of southeast Chicago are still being exposed to ... research team reports. The chemicals do not appear to ... findings appear in the current issue of the Journal ... biosciences scientist Jeff Levengood led the study. Levengood, a ...
... Websites with a Turn-Key Solution for Health Portal ... ... Jan. 16 HealthCare.com,( http://www.healthcare.com ), the leading healthcare provider directory ... MediResource ( http://www.mediresource.com ), a leading creator and,syndicator of interactive health ...
... (TSX:,DAX) (NASDAQ: DRAX ) has received approval from ... Course Issuer Bid (NCIB) to,purchase up to 4,072,054 common ... in the public float as at January 14, 2008.,As ... were issued and,outstanding., Purchases may begin on January ...
... Will Analyze Campaign Speeches and Ads During,Presidential Symposium ... 16 Just prior to the primary,elections in ... and clinician Drew Westen, Ph.D., will describe the,emotional ... the Presidential,Symposium of the American Psychoanalytic Association,s 2008 ...
Cached Medicine News:Health News:DNA Analysis Could Help Customize Treatments for MS 2Health News:Toxoplasma infection increases risk of schizophrenia, study suggests 2Health News:Herons persist in Chicago wetlands despite exposure to banned chemicals 2Health News:Herons persist in Chicago wetlands despite exposure to banned chemicals 3Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 2Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 3Health News:DRAXIS Share Buyback Approved by TSX 2Health News:DRAXIS Share Buyback Approved by TSX 3Health News:DRAXIS Share Buyback Approved by TSX 4Health News:2008 Presidential Campaign on the Couch 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: